Vol. 2 No. 3 (2022)
Reimbursement Recommendations

Colchicine (Myinfla)

Published March 24, 2022

Key Messages

  • CADTH recommends that Myinfla should not be reimbursed by public drug plans for the reduction of atherothrombotic events in adults with coronary artery disease.
  • Evidence from 4 clinical trials in patients with coronary artery disease showed that adding Myinfla to standard preventive treatments lowered patients’ chances of having major cardiovascular events.
  • There was not enough evidence to show that Myinfla reduced mortality, heart attack and/or stroke, or improved health-related quality of life.